Merck

Merck Serono spin-off Quartz Bio to offer biomarker data analysis

Tuesday, September 4, 2012 12:41 PM

Merck Serono, a division of Merck, has created Quartz Bio, the second spin-off company resulting from its Entrepreneur Partnership Program launched in April. Quartz Bio will offer biomarker data management and exploratory biomarker analysis services to the pharmaceutical industry. Biomarker analysis is a critical step in the drug development process, as it enables the identification of patient profiles most responsive to a given treatment.

More... »

EMD Millipore to acquire Biochrom

Thursday, August 23, 2012 09:54 AM

EMD Millipore, the life science division of Merck of Darmstadt, Germany, has decided to acquire Biochrom, a cell culture media specialist of Berlin, Germany. The closing price was not disclosed.

More... »

Ark Therapeutics signs a letter of intent with EMD Millipore

Friday, August 17, 2012 11:13 AM

Ark Therapeutics, a London-based contract development and manufacturing company focused on viral product, has signed a non-binding letter of intent with EMD Millipore, a division of Merck, to enter into a collaborative agreement in the field of viral based bioengineered vaccines and other live viral products manufacturing. 

More... »

PatientsLikeMe, Merck collaborate on evaluating psoriasis impact

Friday, August 17, 2012 09:23 AM

PatientsLikeMe, a social networking health site, has entered into a collaboration with global pharmaceutical company Merck to evaluate the impact of psoriasis on patients and to inform a novel approach to improving outcomes.

More... »

Arrowhead enters into antibody candidate evaluation agreement with Merck

Wednesday, August 15, 2012 11:27 AM

Arrowhead Research, a clinical stage targeted therapeutics company based in Pasadena, Calif., has entered into an agreement with global healthcare company Merck, through a subsidiary, to undertake an evaluation of a novel proprietary therapeutic monoclonal antibody candidate derived from Arrowhead’s human-derived peptide targeting and discovery program.

More... »

PAREXEL appoints Larson as VP of evidence development

Friday, August 3, 2012 12:25 PM

PAREXEL Consulting, a business unit of PAREXEL International and a global consultancy serving the biopharmaceutical and medical device industries, has appointed Leanne R. Larson as vice president of evidence development, a newly created position.

More... »

R-Pharm licenses Merck hepatitis C drug

Friday, July 6, 2012 03:59 PM

The Russian pharmaceutical company R-Pharm—headed by the Ministry of Industry and Trade of the Russian Federation—entered into a licensing agreement with MSD (Merck) for rights to a novel investigational, hepatitis C once-daily protease inhibitor, narlaprevir. 

More... »

Quintiles to offer jobs to 100 Merck Serono employees affected by cuts

Wednesday, June 27, 2012 10:16 AM

CRO Quintiles has committed to make at least 100 employment offers within the next three months to Merck Serono employees primarily working in global development and medical function in Geneva.

More... »

Merck Serono, Compugen establish new biomarker company Neviah Genomics

Monday, June 25, 2012 02:52 PM

Merck Serono of Darmstadt, Germany, and Compugen, a therapeutic product discovery company of Tel Aviv, Israel, have established a novel start-up company called Neviah Genomics, focused on the discovery and development of novel biomarkers for the prediction of drug-induced toxicity.

More... »

Seven global biopharmas form neuroscience consortium

Wednesday, June 20, 2012 02:56 PM

Seven global biopharmaceutical companies have formed the Massachusetts Neuroscience Consortium, which will fund pre-clinical neuroscience at Massachusetts academic and research institutions. Participants include Abbott, Biogen Idec, EMD Serono, Janssen Research & Development, Merck, Pfizer and Sunovion Pharmaceuticals.

More... »